Microvascular and macrovascular complications

Pediatric Diabetes

Volumn 8, Issue 3, 2007, Pages 163-170

  Donaghue, Kim C ^a   Chiarelli, Francesco ^b   Trotta, Daniela ^b   Allgrove, Jeremy ^c   Dahl jorgensen, Knut ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF CHIETI   (Italy)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL TRIAL; CONGENITAL MALFORMATION; COUGHING; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSLIPOPROTEINEMIA; EYE PHOTOGRAPHY; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFESTYLE; LIPID BLOOD LEVEL; LOW LEVEL LASER THERAPY; MASS SCREENING; MICROALBUMINURIA; OPHTHALMOSCOPY; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; URINALYSIS; ADOLESCENT; CARDIOVASCULAR DISEASE; CIRCULATION; COHORT ANALYSIS; METABOLISM; MICROCIRCULATION; PATIENT CARE PLANNING; PRACTICE GUIDELINE; STANDARD; VASCULAR DISEASE;

ADOLESCENT; BLOOD CIRCULATION; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MICROCIRCULATION; PATIENT CARE PLANNING; RISK FACTORS; VASCULAR DISEASES;

EID: 34249864445     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2007.00250.x     Document Type: Article

References (71)

1. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994: 330: 15-18.
2. Mohsin F, Craig ME, Cusumano J et al. Discordant trends in microvascular complications in adolescents with type 1 diabetes from 1990 to 2002. Diabetes Care 2005: 28: 1974-1980.
3. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: A 10-year prospective observational study. Diabetes Care 2002: 25: 859-864.
4. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
5. DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994: 125: 177-188.
6. DCCT/EDIC Writing Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003: 290: 2159-2167
7. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005: 353: 2643-2653.
8. American Diabetes Association. Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care 2003: 26: 2194-2197.
9. Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes 2002: 51: 2637-2641.
10. Makimattila S, Ylitalo K, Schlenzka A et al. Family histories of Type II diabetes and hypertension predict intima-media thickness in patients with Type I diabetes. Diabetologia 2002: 45: 711-718.
11. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med 1985: 78: 785-794.
12. Donaghue KC, Fairchild JM, Craig ME et al. Do all prepubertal years of diabetes duration contribute equally to diabetes complications? Diabetes Care 2003: 26: 1224-1229.
13. Donaghue KC, Craig ME, Chan AK et al. Prevalence of diabetes complications 6 years after diagnosis in an incident cohort of childhood diabetes. Diabet Med 2005: 22: 711-718.
14. Couper JJ, Staples AJ, Cocciolone R, Nairn J, Badcock N, Henning P. Relationship of smoking and albuminuria in children with insulin-dependent diabetes. Diabet Med 1994: 11: 666-669.
15. Gay EC, Cai Y, Gale SM et al. Smokers with IDDM experience excess morbidity. The Colorado IDDM Registry. Diabetes Care 1992: 15: 947-952.
16. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993: 16: 434-444.
17. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998: 351: 1755-1762.
18. Jenkins AJ, Lyons TJ, Zheng D et al. Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathy. Kidney Int 2003: 64: 817-828.
19. Lyons TJ, Jenkins AJ, Zheng D et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004: 45: 910-918.
20. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989: 320: 1161-1165.
21. Soergel M, Kirschstein M, Busch C et al. Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: A multicenter trial including 1141 subjects J Pediatr 1997: 130: 178-184.
22. Dorchy H, Claes C, Verougstraete C. Risk factors of developing proliferative retinopathy in type 1 diabetic patients: Role of BMI. Diabetes Care 2002: 25: 798-799.
23. De Block CE, De Leeuw IH, Van Gaal LF. Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care 2005: 28: 1649-1655.
24. Stone ML, Craig ME, Chan AK, Lee JW, Verge CF, Donaghue KC. Natural history and risk factors for microalbuminuria in adolescents with type 1 diabetes: A longitudinal study. Diabetes Care 2006: 29: 2072-2077.
25. Koivisto VA, Stevens LK, Mattock M et al. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 1996: 19: 689-697.
26. Moy CS, Songer TJ, La Porte RE et al. Insulin-dependent diabetes mellitus, physical activity, and death. Am J Epidemiol 1993: 137: 74-81.
27. Maguire A, Chan A, Cusumano J et al. The case for biennial retinopathy screening in children and adolescents. Diabetes Care 2005: 28: 509-513.
28. Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 2003: 16: 795-800.
29. Maguire A, Cusumano JM, Craig ME, Donaghue KC. The case for biennial retinopathy screening in children and adolescents: Response to Stefánsson. Diabetes Care 2006: 29: 178-179.
30. Klein R, Klein BE, Moss SE, Davis MD, Demets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984: 102: 520-526.
31. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: The second report of diabetic retinopathy study findings. Ophthalmology 1978: 85: 82-106.
32. Hutchinson A, Mc Intosh A, Peters J et al. Effectiveness of screening and monitoring tests for diabetic retinopathy - a systematic review. Diabet Med 2000: 17: 495-506.
33. Moss SE, Klein R, Kessler SD, Richie KA. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology 1985: 92: 62-67.
34. Murgatroyd H, Ellingford A, Cox A et al. Effect of mydriasis and different field strategies on digital image screening of diabetic eye disease. Br J Ophthalmol 2004: 88: 920-924.
35. Bailey CC, Sparrow JM, Grey RH, Cheng H. The National Diabetic Retinopathy Laser Treatment Audit. III. Clinical outcomes. Eye 1999: 13 (Pt 2): 151-159.
36. Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc 1996: 94: 505-537.
37. Mogensen CE, Keane WF, Bennett PH et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995: 346: 1080-1084.
38. Rossing P: The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005: 48: 1439-1444.
39. Ruggenenti P, Remuzzi G. Kidney failure stabilizes after a two-decade increase: Impact on global (renal and cardiovascular) health. Clin J Am Soc Nephrol 2007: 2: 146-150.
40. Mathiesen ER, Oxenboll B, Johansen K, Svendsen PA, Deckert T. Incipient nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 1984: 26: 406-410.
41. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984: 311: 89-93.
42. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982: 1: 1430-1432.
43. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985: 28: 590-596.
44. Valdorf-Hansen F, Jensen T, Borch-Johnsen K, Deckert T. Cardiovascular risk factors in type I (insulin-dependent) diabetic patients with and without proteinuria. Acta Med Scand 1987: 222: 439-444.
45. Amin R, Turner C, van Aken S et al. The relationship between microalbuminuria and glomerular filtration rate in young type 1 diabetic subjects: The Oxford Regional Prospective Study. Kidney Int 2005: 68: 1740-1749.
46. Couper JJ, Clarke CF, Byrne GC et al. Progression of borderline increases in albuminuria in adolescents with insulin-dependent diabetes mellitus. Diabet Med 1997: 14: 766-771.
47. Lurbe E, Sorof JM, Daniels SR. Clinical and research aspects of ambulatory blood pressure monitoring in children. J Pediatr 2004: 144: 7-16.
48. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003: 348: 2285-2293.
49. Rudberg S, Dahlquist G. Determinants of progression of microalbuminuria in adolescents with IDDM. Diabetes Care 1996: 19: 369-371.
50. Zerbini G, Bonfanti R, Meschi F et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes 2006: 55: 2620-2625.
51. Parving HH. Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus. Diabetes Care 1991: 14: 260-269.
52. Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis HP, Parving HH. Improved prognosis in type 1 diabetic patients with nephropathy: A prospective follow-up study. Kidney Int 2005: 68: 1250-1257.
53. Steinberg D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nat Med 2002: 8: 1211-1217.
54. Yoshino G, Kazumi T, Iwai M et al. Recommendation for strict control of plasma triglyceride in diabetic subjects. Diabetes Care 1988: 11: 794-795.
55. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004: 114 (Suppl. 2): 555-576.
56. Wells T, Frame V, Soffer B et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 2002: 42: 870-880.
57. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004: 329: 828.
58. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001: 134: 370-379.
59. Cooper WO, Hernandez-Diaz S, Arbogast PG et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006: 354: 2443-2451.
60. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: A meta-analysis. Diabetes Care 2003: 26: 1895-1901.
61. Laing SP, Swerdlow AJ, Slater SD et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003: 46: 760-765.
62. Jarvisalo MJ, Raitakari M, Toikka JO et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation 2004: 109: 1750-1755.
63. Jenkins AJ, Lyons TJ, Zheng D et al. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: Associations with gender and glycemia. Diabetes Care 2003: 26: 810-818.
64. Idzior-Walus B, Mattock MB, Solnica B, Stevens L, Fuller JH. Factors associated with plasma lipids and lipoproteins in type 1 diabetes mellitus: The EURODIAB IDDM Complications Study. Diabet Med 2001: 18: 786-796.
65. Wadwa RP, Kinney GL, Maahs DM et al. Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care 2005: 28: 1051-1056.
66. Maahs DM, Maniatis AK, Nadeau K, Wadwa RP, Mc Fann K, Klingensmith GJ. Total cholesterol and high-density lipoprotein levels in pediatric subjects with type 1 diabetes mellitus. J Pediatr 2005: 147: 544-546.
67. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial [see comment]. Lancet 2003: 361: 2005-2016.
68. de Jongh S, Ose L, Szamosi T et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002: 106: 2231-2237.
69. Stein EA, Illingworth DR, Kwiterovich PO Jr et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: A randomized controlled trial. JAMA 1999: 281: 137-144.
70. Wiegman A, Hutten BA, de Groot E et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled trial. JAMA 2004: 292: 331-337.
71. Graham DJ, Staffa JA, Shatin D et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004: 292: 2585-2590.